EFFICACY OF ETANERCEPT IN TREATMENT OF VARIOUS TYPES OF JUVENILE IDIOPATHIC ARTHRITIS
https://doi.org/10.15690/vsp.v12i6.885
Abstract
Aim: to assess efficacy and safety of etanercept in treatment of various types of juvenile idiopathic arthritis in children under conditions of real clinical practice. Patients and methods: 52 children were included into the study, among them 16 were with systemic and 36 with juvenile idiopathic arthritis without extra-articular involvement. Results: etanercept treatment was the most efficient in patients with systemic juvenile idiopathic arthritis without extra-articular involvement. In 6 and 12 months of the treatment 50 and 70% improvement according to the ACRpedi criteria were established in 31/36 (86%) and 28/36 (78%) of the patients, respectively. In 24 months in 5 (29%) of 17 children remained in the study remission stage of the diseases was confirmed. Conclusions: etanercept treatment was not associated with significant unfavorable effects, which allows to recommend this drug for treatment of juvenile idiopathic arthritis without extra-articular involvent and resistant to standard anti-rheumatic therapy.
About the Authors
O. Yu. Konopel'ko
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
E. S. Zholobova
I.M. Sechenov First Moscow State Medical University
Russian Federation
Zholobova Elena Spartakovna, Doctor of Medical Science, Professor of the Department of Childhood Illnesses
Russian Federation
Zholobova Elena Spartakovna, Doctor of Medical Science, Professor of the Department of Childhood Illnesses
M. N. Nikolaeva
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
O. S. Rozvadovskaya
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
V. Ya. El'yashevich
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
E. Yu. Afonina
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
References
1. Cassidy J. T., Petty R. E., Laxer R. M. et al. Textbook of pediatric rheuma tology. 6th ed. Philadelphia: Saunders Elsevier. 2010. 794 p.
2. Instructions for medical use of Enbrel (Etanercept), lyophilisate for preparing solution for subcutaneous injection of 25 mg LCR- 006031/09 230709 and 10 mg LP 002122-040713. State Register of Medicinal Products. http://grls.rosminzdrav.ru/ GRLS.aspx.
3. Alekseeva E. I., Bzarova T. M., Valieva S. I. Effektivnost i bezopasnost chelovecheskikh monoklonalnykh antitel k FNO u detey s yuvenilnym idiopaticheskim artritom pri pervichnoy i vtorichnoy neeffektivnosti drugikh genno-inzhenernykh biologicheskikh preparatov [Efficacy and safety of human monoclonal antibodies to TNF in children with juvenile idiopathic arthritis in primary and secondary ineffectiveness of other genetically engineered biological agents]. Voprosy sovremennoy pediatrii — Current Pediatrics. 2012; 11 (4): 82–88.
4. Bracaglia C., Buonuomo P. S., Tozzi Al. E. Safety and efficacy of etanercept in a cohort of patients with juvenile idiopathic arthritis under 4 years of age. J. Rheumatol. 2012; 39: 6.
5. Trachana M., Pratsidou-Gerts P., Badouraki M. Achievement of clinical remission in patients with juvenile idiopathic arthritis under a 2–10-year etanercept exposure. Clin. Rheumatol. 2013. Doi: 10.1007/S10067-013-2261-Z.
6. Kietz D. A., Pepmueller P. H., Moore T. L. Clinical response to etanercept in polyarticular course juvenile rheumatoid arthritis. J. Rheumatol. 2001; 28: 360–362.
7. Lovell D. J., Reiff A., Ilowite N. T., Wallace C. A. et al. Safety and efficacy of up to eight years of continuous Etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008; 58; 5: 1496–1504.
8. Dempster H., Porepa M., Young N., Feldman B. M. The clinical meaning of functional outcome scores in children with juvenile arthritis. Arthritis Rheum. 2001; 44 (8): 1768–1774.
Review
For citations:
Konopel'ko O.Yu., Zholobova E.S., Nikolaeva M.N., Rozvadovskaya O.S., El'yashevich V.Ya., Afonina E.Yu. EFFICACY OF ETANERCEPT IN TREATMENT OF VARIOUS TYPES OF JUVENILE IDIOPATHIC ARTHRITIS. Current Pediatrics. 2013;12(6):115-119. (In Russ.) https://doi.org/10.15690/vsp.v12i6.885
Views:
836
Email this article 
